GlassScriptPhysician profile
Basilisa Pacheco
NPI 1790023570
$4,036.08
in general payments reported to CMS, 2019-2025
27 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $409 · 2023: $931 · 2024: $1,253 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,106 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,106.23 |
| Education | $212.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,219.39 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $633.34 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Inspire Medical Systems, INC. | $262.51 | 2024-2025 | Inspire |
| Mylan Specialty L.P. | $249.99 | 2022-2024 | Yupelri |
| Insmed, INC. | $237.51 | 2021-2025 | Arikayce |
| Philips North America LLC | $213.11 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Regeneron Healthcare Solutions, INC. | $146.98 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.92 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Amgen INC. | $116.86 | 2023-2025 | Tezspire |
| United Therapeutics Corporation | $112.23 | 2021-2025 | Tyvaso, Tyvaso |
| Novartis Pharmaceuticals Corporation | $105.76 | 2023-2024 | |
| Genzyme Corporation | $99.38 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $97.99 | 2025 | |
| Verona Pharma, INC. | $67.84 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $58.73 | 2025 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $41.96 | 2023-2025 | Prolastin-C Liquid |
| Covis Pharma Gmbh | $38.62 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $32.18 | 2025 | Purified Cortrophin Gel |
| Ethicon INC. | $29.56 | 2022 | |
| Baxter Healthcare | $20.25 | 2023 | Hillrom - Life 2000 Ventilation System |
| Lilly USA, LLC | $19.48 | 2025 | Zepbound |
| Actelion Pharmaceuticals US, INC. | $17.00 | 2024 | Opsumit |
| Mallinckrodt Hospital Products INC. | $16.89 | 2023 | Acthar |
| Paratek Pharmaceuticals, INC. | $15.38 | 2023 | Nuzyra |
| Jazz Pharmaceuticals INC. | $15.25 | 2021 | |
| Axsome Therapeutics, INC. | $14.20 | 2023 | Sunosi |
| Sunovion Pharmaceuticals INC. | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basilisa Pacheco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.